The GAVURD system serves an important role in prioritizing candidate non-coding causal variants for unresolved rare disease that can serve as the high value and informed focus of additional functional follow-up studies.
Abstract
Unresolved rare disease is a major public health challenge affecting ∼300 million people worldwide. At least 50% of these individuals remain genetically unresolved after applying exome sequencing and/or whole genome sequencing. One source of these missing diagnoses is the presence of rare variants within the non-coding genome that are detected but not interpreted by whole genome sequencing. In order to systematically evaluate candidate pathogenic non-coding variants, we created the Genomic Analysis of Variants in Unresolved Rare Disease (GAVURD) system. GAVURD leverages trio whole genome sequencing alignment data to produce a short list of putative pathogenic non-coding variants for a given proband. GAVURD uses best practices for de novo and rare inherited variant identification, links variants to human disease genes harnessing topologically associated domain (TAD) data, and rank prioritizes variants based on phenotypic overlap. As a proof-of-concept, we applied GAVURD to ten probands with unresolved rare disease and implicated six potentially causal non-coding variants based on a confluence of evidence supportive of pathogenicity. The GAVURD system serves an important role in prioritizing candidate non-coding causal variants for unresolved rare disease that can serve as the high value and informed focus of additional functional follow-up studies.
These findings demonstrate that leveraging whole-genome sequencing in large-scale biobanks enables the identification of rare protein-coding variants, genes, and gene sets associated with AML.
S. Vieno, M. Singh, S. Kramer et al.· medRxiv· 0 citations
Despite the introduction of genome sequencing (GS) for rare disease diagnostics, a genetic cause is not identified in most patients. Here, we explored the potential of proteomics to improve the diagnostic yield in 424 patients with rare diseases from the 100,000 Genomes Project (100kGP) without a genetic diagnosis. Ser...
J. Carrasco-Zanini, J. Andrade, M. Pietzner et al.· Science Translational Medici...· 0 citations
It is demonstrated that LRS-based SV analysis, supported by orthogonal SRS re-analysis, can resolve clinically significant SVs in families who remain unsolved after standard rare disease testing.
P. Dutta, A. Pagnamenta, Christelle Robert et al.· European Journal of Human Ge...· 0 citations
RGP demonstrates that a research-based, patient-driven remote sequencing study can effectively bridge a diagnostic gap for rare disease families underserved in current clinical care and underscores the clinical utility of GS with frequent re-analysis.
A. O'Donnell-Luria, S. DiTroia, Melanie C. O'Leary et al.· medRxiv· 0 citations
This work describes the full spectrum of genetic variation and shows that while 99% of the variants between any two genomes are single base-pair substitutions, 88% of the euchromatic variant base pairs are SVs, including insertions, deletions, duplications, and inversions.
J. Lin, J. Gustafson, J. Wertz et al.· medRxiv· 0 citations
Purpose Children with suspected rare genetic disorders often remain undiagnosed after exome, gene panel, or chromosomal microarray testing. We sought to define recurrent missed-diagnosis mechanisms and evaluate an integrated clinical-genomic reanalysis framework. Methods We studied 75 participants with rare or striking...
Hong-Qiu Gu, A. Sabo, S. Jangam et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.